New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Liquidia Technologies, Inc.

Contributing Author

Recent Articles by Liquidia Technologies, Inc.

Jan-27	Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress LQDA GlobeNewswire
Jan-09	Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update LQDA GlobeNewswire
Jan-07	Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference LQDA GlobeNewswire
Nov-03	Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences LQDA GlobeNewswire
Nov-03	Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update LQDA GlobeNewswire
Oct-27	Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 LQDA GlobeNewswire
Oct-07	Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 LQDA GlobeNewswire
Sep-29	Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting LQDA GlobeNewswire
Sep-11	Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium LQDA GlobeNewswire
Aug-27	Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference LQDA GlobeNewswire
Aug-12	Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update LQDA GlobeNewswire
Aug-05	Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 LQDA GlobeNewswire
Jun-23	Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA LQDA GlobeNewswire
Jun-02	Liquidia Schedules First Commercial Shipment of YUTREPIA (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD LQDA GlobeNewswire
May-28	Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference LQDA GlobeNewswire
May-23	U.S. FDA Approves Liquidia's YUTREPIA (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) LQDA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.